76 related articles for article (PubMed ID: 34866654)
1. Ligand-based quantitative structural assessments of SARS-CoV-2 3CL
Adhikari N; Banerjee S; Baidya SK; Ghosh B; Jha T
J Mol Struct; 2022 Mar; 1251():132041. PubMed ID: 34866654
[TBL] [Abstract][Full Text] [Related]
2. Robust classification-based molecular modelling of diverse chemical entities as potential SARS-CoV-2 3CL
Adhikari N; Banerjee S; Baidya SK; Ghosh B; Jha T
SAR QSAR Environ Res; 2021 Jun; 32(6):473-493. PubMed ID: 34011224
[TBL] [Abstract][Full Text] [Related]
3. QSAR based virtual screening derived identification of a novel hit as a SARS CoV-229E 3CL
Jawarkar RD; Bakal RL; Zaki MEA; Al-Hussain S; Ghosh A; Gandhi A; Mukerjee N; Samad A; Masand VH; Lewaa I
Arab J Chem; 2022 Jan; 15(1):103499. PubMed ID: 34909066
[TBL] [Abstract][Full Text] [Related]
4. Potential inhibitors of coronavirus 3-chymotrypsin-like protease (3CL
Gyebi GA; Ogunro OB; Adegunloye AP; Ogunyemi OM; Afolabi SO
J Biomol Struct Dyn; 2021 Jun; 39(9):3396-3408. PubMed ID: 32367767
[TBL] [Abstract][Full Text] [Related]
5. Study on the mechanism of active components of Liupao tea on 3CL
Ni WJ; Chen XX; Wei SY; Lan LL; Qiu RJ; Ling YP; Zhou DS; Wu ZM; Cao ZH; Yu CP; Zeng Y
J Food Biochem; 2021 May; 45(5):e13707. PubMed ID: 33760271
[TBL] [Abstract][Full Text] [Related]
6. Computational modeling of the bat HKU4 coronavirus 3CL
Abuhammad A; Al-Aqtash RA; Anson BJ; Mesecar AD; Taha MO
J Mol Recognit; 2017 Nov; 30(11):. PubMed ID: 28608547
[TBL] [Abstract][Full Text] [Related]
7. The inhibitory effect of some natural bioactive compounds against SARS-CoV-2 main protease: insights from molecular docking analysis and molecular dynamic simulation.
Abdelrheem DA; Ahmed SA; Abd El-Mageed HR; Mohamed HS; Rahman AA; Elsayed KNM; Ahmed SA
J Environ Sci Health A Tox Hazard Subst Environ Eng; 2020; 55(11):1373-1386. PubMed ID: 32998618
[TBL] [Abstract][Full Text] [Related]
8. QSAR and molecular docking studies of isatin and indole derivatives as SARS 3CL
Soleymani N; Ahmadi S; Shiri F; Almasirad A
BMC Chem; 2023 Apr; 17(1):32. PubMed ID: 37024955
[TBL] [Abstract][Full Text] [Related]
9. An Integrated Computational and Experimental Approach to Identifying Inhibitors for SARS-CoV-2 3CL Protease.
Zhai T; Zhang F; Haider S; Kraut D; Huang Z
Front Mol Biosci; 2021; 8():661424. PubMed ID: 34079818
[TBL] [Abstract][Full Text] [Related]
10. Why Are Lopinavir and Ritonavir Effective against the Newly Emerged Coronavirus 2019? Atomistic Insights into the Inhibitory Mechanisms.
Nutho B; Mahalapbutr P; Hengphasatporn K; Pattaranggoon NC; Simanon N; Shigeta Y; Hannongbua S; Rungrotmongkol T
Biochemistry; 2020 May; 59(18):1769-1779. PubMed ID: 32293875
[TBL] [Abstract][Full Text] [Related]
11. Proposing a fungal metabolite-flaviolin as a potential inhibitor of 3CL
Rao P; Shukla A; Parmar P; Rawal RM; Patel BV; Saraf M; Goswami D
J Biomol Struct Dyn; 2022 Jan; 40(1):348-360. PubMed ID: 32875950
[TBL] [Abstract][Full Text] [Related]
12. Identification of lead compounds from large natural product library targeting 3C-like protease of SARS-CoV-2 using E-pharmacophore modelling, QSAR and molecular dynamics simulation.
Elekofehinti OO; Iwaloye O; Molehin OR; Famusiwa CD
In Silico Pharmacol; 2021; 9(1):49. PubMed ID: 34395160
[TBL] [Abstract][Full Text] [Related]
13.
Khan PM; Kumar V; Roy K
Comb Chem High Throughput Screen; 2021; 24(8):1281-1299. PubMed ID: 32928086
[TBL] [Abstract][Full Text] [Related]
14. Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2
Khan SA; Zia K; Ashraf S; Uddin R; Ul-Haq Z
J Biomol Struct Dyn; 2021 Apr; 39(7):2607-2616. PubMed ID: 32238094
[TBL] [Abstract][Full Text] [Related]
15. Rational approach toward COVID-19 main protease inhibitors via molecular docking, molecular dynamics simulation and free energy calculation.
Keretsu S; Bhujbal SP; Cho SJ
Sci Rep; 2020 Oct; 10(1):17716. PubMed ID: 33077821
[TBL] [Abstract][Full Text] [Related]
16. Potential In Vitro Inhibition of Selected Plant Extracts against SARS-CoV-2 Chymotripsin-Like Protease (3CL
Guijarro-Real C; Plazas M; RodrÃguez-Burruezo A; Prohens J; Fita A
Foods; 2021 Jun; 10(7):. PubMed ID: 34209659
[TBL] [Abstract][Full Text] [Related]
17. Development of a simple, interpretable and easily transferable QSAR model for quick screening antiviral databases in search of novel 3C-like protease (3CLpro) enzyme inhibitors against SARS-CoV diseases.
Kumar V; Roy K
SAR QSAR Environ Res; 2020 Jul; 31(7):511-526. PubMed ID: 32543892
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of SARS-CoV-2 main protease 3CL
Elzupir AO
J Mol Struct; 2020 Dec; 1222():128878. PubMed ID: 32834113
[TBL] [Abstract][Full Text] [Related]
19. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
Froggatt HM; Heaton BE; Heaton NS
J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
[TBL] [Abstract][Full Text] [Related]
20. "Identification of Nafamostat and VR23 as COVID-19 drug candidates by targeting 3CL
Bhowmik D; Sharma RD; Prakash A; Kumar D
J Mol Struct; 2021 Jun; 1233():130094. PubMed ID: 33612858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
